Volume 28, Supplement—December 2022
Contribution of PEPFAR-Supported HIV and TB Molecular Diagnostic Networks to COVID-19 Testing Preparedness in 16 Countries
|Country||No. PEPFAR laboratories||No. (%) PEPFAR laboratories conducting SARS-CoV-2 testing||No. instruments||No. HIV VL and EID tests conducted in PEPFAR laboratories†||No. SARS-CoV-2 tests conducted in PEPFAR laboratories||No. SARS-CoV-2 tests conducted nationally (5)||% SARS-CoV-2 tests performed at PEPFAR laboratories‡|
|Angola||2||2 (100)||2||NA||No data||NA||NA|
|Cameroon||13||10 (77)||7||NA||No data||NA||NA|
|DRC||6||5 (83)||2||176,249||5,565||No data||NA|
|Eswatini||4||1 (25)||1||NA||No data||NA||NA|
|Lesotho||6||3 (50)||0||189,631||47,006||No data||NA|
|Namibia||8||4 (50)||3||NA||No data||NA||NA|
|South Sudan||1||0 (0)||0||NA||0||NA||NA|
*DR, Dominican Republic; DRC, Democratic Republic of Congo; EID, early infant diagnosis; NA, not applicable; PEPFAR, US President’s Emergency Plan for AIDS Relief; VL, viral load. †Number of HIV VL and EID and national SARS-CoV-2 tests are only shown for those countries reporting SARS-CoV-2 testing volumes in PEPFAR-supported laboratories. For countries not reporting SARS-CoV-2 testing volumes in PEPFAR-supported laboratories, HIV VL and EID and national SARS-CoV-2 test numbers are listed as NA. ‡ Percentage of SARS-CoV-2 tests performed at PEPFAR-supported laboratories was only calculated for countries with data available for both PEPFAR and national SARS-CoV-2 testing numbers. For countries without both PEPFAR and national SARS-CoV-2 testing numbers available, % of SARS-CoV-2 tests performed at PEPFAR laboratories is listed as NA. §National SARS-CoV-2 test numbers represent the number of PCR tests. ¶Test type for national SARS-CoV-2 test numbers was uncited or listed as unclear. #National SARS-CoV-2 test numbers represent the number of PCR and antigen tests.
- US President’s Emergency Plan for AIDS Relief. Where we work. 2021 [cited 2021 Nov 4]. https://www.state.gov/where-we-work-pepfar
- World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19, 11 March 2020 [cited 2021 Nov 4]. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
- US President’s Emergency Plan for AIDS Relief. PEPFAR technical guidance in context of COVID-19 pandemic. 2020 Mar 25 [cited 2021 Nov 4]. https://www.state.gov/wp-content/uploads/2020/03/PEPFAR-Technical-Guidance-in-Context-of-COVID-19-Pandemic_03.25.20.pdf
- Nkengasong J. Let Africa into the market for COVID-19 diagnostics. Nature. 2020;580:565.
- Hasell J, Mathieu E, Beltekian D, Macdonald B, Giattino C, Ortiz-Ospina E, et al. A cross-country database of COVID-19 testing. Sci Data. 2020;7:345.
- Degli-Angeli E, Dragavon J, Huang ML, Lucic D, Cloherty G, Jerome KR, et al. Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance. J Clin Virol. 2020;129:
- Federal Drug Administration. In vitro diagnostics EUAs. Molecular diagnostic tests for SARS-CoV-2. 2021 [cited 2021 Sep 24]. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2
- Hans L, Steegen K, Ketseoglou I, Mahlumba Z, Cassim N, Wiggill T, et al. Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory. Int J Infect Dis. 2021;110:1–3.
- Hirschhorn JW, Kegl A, Dickerson T, Glen WB Jr, Xu G, Alden J, et al. Verification and validation of SARS-CoV-2 assay performance on the Abbott m2000 and Alinity m systems. J Clin Microbiol. 2021;59:e03119–20.
- Kogoj R, Kmetič P, Oštrbenk Valenčak A, Fujs Komloš K, Seme K, Sagadin M, et al. Real-life head-to-head comparison of performance of two high-throughput automated assays for the detection of SARS-CoV-2 RNA in nasopharyngeal swabs: the Alinity m and cobas 6800 SARS-CoV-2 assays. J Mol Diagn. 2021;23:920–8.
- World Health Organization. WHO emergency use listing for in vitro diagnostics (IVDs) detecting SARS-CoV-2. 2021 [cited 2020 Sep 24]. https://extranet.who.int/pqweb/sites/default/files/documents/210430_EUL_SARS-CoV-2_product_list.pdf
- World Health Organization. Global tuberculosis report 2021. 2021 Oct 14 [cited 2021 Nov 4]. https://www.who.int/publications/i/item/9789240037021
- Soko RN, Burke RM, Feasey HRA, Sibande W, Nliwasa M, Henrion MYR, et al. Effects of coronavirus disease pandemic on tuberculosis notifications, Malawi. Emerg Infect Dis. 2021;27:1831–9.
- Aziz AB, Raqib R, Khan WA, Rahman M, Haque R, Alam M, et al. Integrated control of COVID-19 in resource-poor countries. Int J Infect Dis. 2020;101:98–101.
- Kavanagh MM, Erondu NA, Tomori O, Dzau VJ, Okiro EA, Maleche A, et al. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet. 2020;395:1735–8.
- Nichols K, Girdwood SJ, Inglis A, Ondoa P, Sy KTL, Benade M, et al. Bringing data analytics to the design of optimized diagnostic networks in low- and middle-income countries: process, terms and definitions. Diagnostics (Basel). 2020;11: